Elpiscience has pioneered a globally leading pipeline of groundbreaking immunotherapies, focusing on critical targets to address the significant unmet clinical needs in oncology and autoimmune diseases.
-
Oncology Program
-
AssetTargetProgramDiscoveryPreclinicalPhase 1Phase 2Phase 3Partner
ES104
VEGF/DLL4BTC, CRC, OC
ES102OX40NSCLC, HNSCC
ES014CD39/TGF-βSolid TumorsES009LILRB2Solid TumorsES004SIRPαSolid TumorsES019 (BiME®)SIRPα/PD-L1Solid Tumors
BiME® FranchiseSIRPα/Multi-targetsSolid Tumors -
-
Autoimmune Program
-
AssetTargetProgramDiscoveryPreclinicalPhase 1Phase 2Phase 3Partner
ES301Fusion proteinAutoimmuneES302TL1A/IL23p19IBDES303TL1A/Target-XAutoimmune -